{"id":"https://openalex.org/W2404476850","doi":"https://doi.org/10.1017/s1092852900009883","title":"Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders","display_name":"Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders","alternate_titles":[],"publication_year":2005,"publication_date":"2005-01-01","ids":{"openalex":"https://openalex.org/W2404476850","doi":"https://doi.org/10.1017/s1092852900009883","mag":"2404476850","pmid":"https://pubmed.ncbi.nlm.nih.gov/15618945"},"language":"en","primary_location":{"id":"doi:10.1017/s1092852900009883","doi":"https://doi.org/10.1017/s1092852900009883","is_oa":false,"landing_page_url":"https://doi.org/10.1017/s1092852900009883","pdf_url":null,"source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2404476850"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107118809","display_name":"Nancy Almand Ator","orcid":"https://orcid.org/0000-0001-7969-1470","observed_orcids":["https://orcid.org/0000-0001-7969-1470"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Nancy A. Ator","raw_affiliation_strings":["Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Hopkins Bayview Campus, Baltimore, MD 21224-6823, USA. ator@jhmi.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Hopkins Bayview Campus, Baltimore, MD 21224-6823, USA. ator@jhmi.edu","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5107118809"],"corresponding_institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436"],"apc_list":{"value":3550,"currency":"USD","value_usd":3550},"apc_paid":null,"fwci":0.4318,"has_fulltext":false,"cited_by_count":64,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.36898396,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"10","issue":"1","first_page":"31","last_page":"39"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.864300012588501,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.864300012588501,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.022099999710917473,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.017899999395012856,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gabaa-receptor-subtypes","display_name":"GABAA receptor subtypes","score":0.9470000267028809},{"id":"https://openalex.org/keywords/benzodiazepines","display_name":"benzodiazepines","score":0.9089999794960022},{"id":"https://openalex.org/keywords/abuse-potential","display_name":"abuse liability","score":0.8840000033378601},{"id":"https://openalex.org/keywords/anxiolytics","display_name":"anxiolytics","score":0.7839999794960022},{"id":"https://openalex.org/keywords/sleep-disturbance","display_name":"sleep disorders","score":0.8820000290870667},{"id":"https://openalex.org/keywords/anxiety-disorders","display_name":"anxiety disorders","score":0.8450000286102295},{"id":"https://openalex.org/keywords/medication-scheduling","display_name":"drug scheduling","score":0.6690000295639038},{"id":"https://openalex.org/keywords/barbiturates","display_name":"barbiturates","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.7174426317214966},{"id":"https://openalex.org/C3018251022","wikidata":"https://www.wikidata.org/wiki/Q3184856","display_name":"Abuse liability","level":3,"score":0.715523362159729},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.6032408475875854},{"id":"https://openalex.org/C2777834853","wikidata":"https://www.wikidata.org/wiki/Q96776939","display_name":"Liability","level":2,"score":0.46620973944664},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41787198185920715},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3843507766723633},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.3829280734062195},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3811102509498596},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3308503031730652},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2283737063407898},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.09634339809417725},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001008","descriptor_name":"Anxiety Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011963","descriptor_name":"Receptors, GABA-A","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D012646","descriptor_name":"Self Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012893","descriptor_name":"Sleep Wake Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016365","descriptor_name":"Liability, Legal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018757","descriptor_name":"GABA Modulators","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018757","descriptor_name":"GABA Modulators","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018757","descriptor_name":"GABA Modulators","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1017/s1092852900009883","doi":"https://doi.org/10.1017/s1092852900009883","is_oa":false,"landing_page_url":"https://doi.org/10.1017/s1092852900009883","pdf_url":null,"source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},{"id":"pmid:15618945","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15618945","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS spectrums","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4581636261","display_name":"Functional Analysis of GABAerglc Sedative/Anxiolytics","funder_award_id":"R01DA004133","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":60,"referenced_works":["https://openalex.org/W77194413","https://openalex.org/W349630348","https://openalex.org/W1487305712","https://openalex.org/W1515177778","https://openalex.org/W1584229443","https://openalex.org/W1905175440","https://openalex.org/W1915339567","https://openalex.org/W1929995708","https://openalex.org/W1941552569","https://openalex.org/W1961680966","https://openalex.org/W1964390380","https://openalex.org/W1965666249","https://openalex.org/W1966341496","https://openalex.org/W1966462692","https://openalex.org/W1972138802","https://openalex.org/W1973275366","https://openalex.org/W1973680070","https://openalex.org/W1977549092","https://openalex.org/W1987802056","https://openalex.org/W1994785056","https://openalex.org/W1998515862","https://openalex.org/W2001619275","https://openalex.org/W2006750873","https://openalex.org/W2012011634","https://openalex.org/W2014017755","https://openalex.org/W2014723035","https://openalex.org/W2018087603","https://openalex.org/W2027098651","https://openalex.org/W2027127607","https://openalex.org/W2035752831","https://openalex.org/W2047516605","https://openalex.org/W2061744957","https://openalex.org/W2063548396","https://openalex.org/W2064636484","https://openalex.org/W2066012888","https://openalex.org/W2067477289","https://openalex.org/W2075743352","https://openalex.org/W2078134267","https://openalex.org/W2079637050","https://openalex.org/W2082111758","https://openalex.org/W2084091336","https://openalex.org/W2091531361","https://openalex.org/W2093617247","https://openalex.org/W2122755849","https://openalex.org/W2263080779","https://openalex.org/W2263877944","https://openalex.org/W2265094805","https://openalex.org/W2277672757","https://openalex.org/W2279724886","https://openalex.org/W2290279581","https://openalex.org/W2316701476","https://openalex.org/W2323660024","https://openalex.org/W2330404768","https://openalex.org/W2346692675","https://openalex.org/W2355822036","https://openalex.org/W2405413470","https://openalex.org/W2410548052","https://openalex.org/W2412207024","https://openalex.org/W2441453331","https://openalex.org/W4302442324"],"related_works":["https://openalex.org/W4315796878","https://openalex.org/W47680410","https://openalex.org/W2023858456","https://openalex.org/W2040995746","https://openalex.org/W119935300","https://openalex.org/W2129874579","https://openalex.org/W1600748339","https://openalex.org/W2405413470","https://openalex.org/W2022871430","https://openalex.org/W2025429574"],"abstract_inverted_index":{"When":[0],"benzodiazepines":[1],"(BZs)":[2],"supplanted":[3],"barbiturates":[4],"as":[5],"a":[6,93],"favored,":[7],"safer":[8],"treatment":[9,102],"for":[10,70,96,103,154],"anxiety":[11,104],"and":[12,21,76],"sleep":[13],"disorders":[14,105],"in":[15,47,53,73,87,106,131,137],"the":[16,18,33,44,48,64,67,74,107,123],"1960s,":[17],"abuse":[19,110,146],"liability":[20,111,147],"dependence":[22,113],"potential":[23],"of":[24,32,35,38,63,66,84,109,122,140,145],"these":[25,57],"drugs":[26,97],"were":[27],"little":[28],"understood.":[29],"Widespread":[30],"recognition":[31],"difficulty":[34],"stopping":[36],"use":[37],"chronically":[39],"taken":[40],"BZs":[41],"emerged":[42],"through":[43],"popular":[45],"press":[46],"late":[49],"1970s,":[50],"which":[51],"resulted":[52],"reluctance":[54],"to":[55,143,149],"prescribe":[56],"otherwise":[58],"clinically":[59],"useful":[60],"compounds.":[61],"Evolution":[62],"understanding":[65],"biochemical":[68],"basis":[69],"BZ":[71],"effects":[72],"1980s":[75],"1990s,":[77],"coupled":[78],"with":[79],"regulatory":[80],"emphasis":[81],"on":[82],"collection":[83],"data":[85],"used":[86],"legal":[88],"scheduling":[89],"decisions,":[90],"made":[91],"possible":[92],"targeted":[94],"search":[95],"that":[98,116],"would":[99],"provide":[100],"effective":[101],"absence":[108],"or":[112],"potential.":[114],"Compounds":[115],"have":[117],"selective":[118],"efficacy":[119],"at":[120],"subtypes":[121],"gamma-aminobutyric":[124],"acid":[125],"type":[126],"A":[127],"receptor,":[128],"are":[129],"active":[130],"preclinical":[132,138],"anxiolytic":[133],"screens,":[134],"but":[135],"negative":[136],"studies":[139],"behavior":[141],"relevant":[142],"evaluation":[144],"appear":[148],"be":[150],"one":[151],"promising":[152],"means":[153],"achieving":[155],"this":[156],"end.":[157]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2404476850","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
